Shares of OncoMed Pharmaceuticals plummeted 25% on 13 June after the cancer drug developer revealed it had voluntarily stopped patient enrollment and dosing in its ongoing Phase I trials testing two Wnt pathway inhibitors – vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) – following reports of mild-to-moderate adverse bone-related events.
Shares of OncoMed Pharmaceuticals plummeted 25% on 13 June after the cancer drug developer revealed it had voluntarily stopped patient enrollment and dosing in its ongoing Phase I trials testing two Wnt pathway inhibitors – vantictumab (anti-Fzd7, OMP-18R5) and Fzd8-Fc (OMP-54F28) – following reports of mild-to-moderate adverse bone-related events.
The FDA late in the day slapped a partial hold on the Phase I trials of vantictumab until revised protocols...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
